Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INM-755 (cannabinol) cream
INM-755 · 1 trial · 4 indications
Patients will report peak (maximal) pruritus intensity over the previous 24 hours using a 100 mm VAS (0 being "no itch" to 100 mm being "worst imaginable itch") recorded daily in the study diary. This outcome measure is applicable only for patients with non-wound index areas with eligible (moderate to severe) itch.
Wound surface area will be measured by digital photography at weekly intervals. This outcome measure is applicable only for patients with wound index areas.
Patients will report wound pain intensity using a 100 mm VAS (0 being "no pain" to 100 mm being "worst imaginable pain") and this will be recorded in the study diary. Procedural pain will be assessed immediately after each wound dressing, which may be every 1, 2, or 3 days according to an individual patient's schedule for dressing change. This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) procedural pain.
Patients will report wound pain intensity using a 100 mm VAS (0 being "no pain" to 100 mm being "worst imaginable pain") and this will be recorded in the study diary. Peak (maximal) background pain will be assessed daily in the morning (done before the dressing change). This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) background pain.
Patients will report peak (maximal) pruritus intensity over the previous 24 hours using a 100 mm VAS (0 being "no itch" to 100 mm being "worst imaginable itch") recorded daily in the study diary. This outcome measure is applicable only for patients with wound index areas associated with eligible (moderate to severe) itch.
| Arm | Type | Description |
|---|---|---|
| INM-755 (cannabinol) cream | EXPERIMENTAL | Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period. |
| Vehicle cream | PLACEBO_COMPARATOR | Vehicle cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period. |
| Name | Type | Description |
|---|---|---|
| INM-755 (cannabinol) cream | DRUG | topical cream containing cannabinol for dermal application |
| Vehicle Cream | DRUG | topical cream base for dermal application containing no active agent |
Key Inclusion Criteria: * Male or female patients aged ≥18 years with documented diagnosis of any of the following types of inherited EB: Simplex, Junctional, Dystrophic, Kindler. Enrolment will be extended to patients ≥12 years old and \<18 years old after positive opinion of a data monitoring com...
INM-755 is an investigational topical cream being developed for the treatment of epidermolysis bullosa, a group of rare genetic skin blistering disorders. The Phase 2 trial evaluated it in epidermolysis bullosa simplex as well as junctional epidermolysis bullosa, dystrophic epidermolysis bullosa, and Kindler syndrome.
INM-755 is being developed by InMed Pharmaceuticals Inc., a biopharmaceutical company that trades under the ticker symbol INM. InMed is advancing INM-755 as a cannabinol-based topical cream for rare skin diseases.
INM-755 has completed a Phase 2 clinical trial. It is an investigational product and has not been approved by the FDA. The Phase 2 study, NCT04908215, has been completed and no active trials of INM-755 are currently listed.
INM-755 has been studied in one clinical trial, NCT04908215, titled "INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa." This completed Phase 2 trial enrolled 19 participants across France, Germany, Greece, Israel, and Italy, and was randomized, double-blind, and placebo-controlled.
Yes, INM-755 (cannabinol) cream is another name for INM-755. The parenthetical "cannabinol" refers to the active ingredient, cannabinol, formulated as a topical cream. Both names refer to the same investigational product developed by InMed Pharmaceuticals.